comprehensive genomic profiles of small cell lung cancer

Prospective Clinical Validation of the InVisionFirst

Non–small-cell lung cancer (NSCLC) accounts for more than 85% of lung cancer 1 the majority of patients present with advanced-stage disease and are treated with systemic therapies Great strides have been made in the development of therapies for such patients including targeted therapies and

Progress in Small Cell Lung Cancer (SCLC): Working Group

Expand comprehensive genomic profiling studies of clinically -annotated SCLC specimens to Genomic profiles of SCLC (George et al Nature 2015) SCLC subsets defined by lineage transcription factors Progress in Small Cell Lung Cancer (SCLC):

Abstract A101: Comprehensive genomic profile analyses

Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics November 5-9 2015 Boston MA Small Cell Lung Cancers (SCLC) are fast growing tumors with frequent neuroendocrine differentiation They represent 10-15% of lung cancers and arise in heavy smokers Most SCLC cancer patients respond well to chemotherapy initially but rapidly develop

Epigenomic profiling of non

Background: Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide and is primarily treated with radiation surgery and platinum-based drugs like cisplatin and carboplatin The major challenge in the treatment of NSCLC patients is intrinsic or acquired resistance to chemotherapy Molecular markers predicting the outcome of the patients are urgently

Delivering comprehensive genomic profiling for clinical

For example for advanced non–small cell lung carcinoma (NSCLC) the 2011 National Comprehensive Cancer Network (NCCN ) guidelines for molecular profiling recommended multiple assays for genomic alterations in only 3 genes: KRAS (base substitution in codon 12) EGFR (in-frame indels base substitutions and copy number alterations) and EML4-ELK (rearrangements) This required multiple

Genomic Landscape Survey Identifies SRSF1 as a Key

Introduction Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of lung cancer worldwide with more than 180 000 cases per year [] It is an aggressive neuroendocrine malignancy with a unique natural history of a short doubling time high growth fraction and early development of widespread metastases [] Most patients are very sensitive to thoracic radiotherapy

1138PDImmune checkpoint inhibitor (ICPI) efficacy and

Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC) Annals of Oncology Volume 28 Issue (14 2%) with immune evasion profiles (p 0 05

Genomic and pathological heterogeneity in clinically

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations Atsuko Ogino Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA USA

Comprehensive genomic profiles of small cell lung cancer

06 08 2015We have sequenced the genomes of 110 small cell lung cancers (SCLC) one of the deadliest human cancers In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1 sometimes by complex genomic rearrangements Two tumours with wild-type RB1 had evidence of chromothripsis leading to overexpression of cyclin D1 (encoded by the CCND1 gene) revealing an

Cancer gene profiling in non

Lung cancer remains the most prevalent cancer and the leading cause of cancer mortality with an estimated 222 500 new cases and 156 000 deaths in the United States in 2017 [] There are two major histological classes of lung cancers: non-small-cell lung cancer (NSCLC) accounting for approximately 85–90% and small-cell lung cancers (SCLC) accounting for 10–15%

Abstract 3411: Genomic profiling of non

Proceedings: AACR Annual Meeting 2019 March 29-April 3 2019 Atlanta GA Background Xuanwei a rural county is located in the northeast of Yunnan Province China According to a national retrospective survey on cancer mortality during 1973-1975 the highest mortality rate of lung cancer in Xuanwei was 5 3 times higher than that in rural areas nationwide Age standardized mortality rates

UpToDate

Small cell lung cancer (SCLC) is distinguished from non-small cell lung cancer by its rapid doubling time high growth fraction and the early development of widespread metastases Although the cancer is initially highly responsive to chemotherapy and radiotherapy the majority of patients will relapse with broadly resistant disease within a few months to a year from initial therapy

Circular RNA circSATB2 promotes progression of non

Lung cancer has high morbidity and mortality worldwide with non-small cell lung cancer (NSCLC) accounting for 85% of the cases Therapies for lung cancer have relatively poor outcomes and further improvements are required Circular RNAs have been reported to participate in the occurrence and progression of cancer Information on the functions and mechanism of circRNAs in lung cancer is

Dipsit Digital de la Universitat de Barcelona

Lung cancer: Issue Date: 6-Aug-2015: Publisher: Nature Publishing Group: Abstract: We have sequenced the genomes of 110 small cell lung cancers (SCLC) one of the deadliest human cancers In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1 sometimes by complex genomic rearrangements

Genomic Landscape Survey Identifies SRSF1 as a Key

Introduction Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of lung cancer worldwide with more than 180 000 cases per year [] It is an aggressive neuroendocrine malignancy with a unique natural history of a short doubling time high growth fraction and early development of widespread metastases [] Most patients are very sensitive to thoracic radiotherapy

Abstract 3411: Genomic profiling of non

Proceedings: AACR Annual Meeting 2019 March 29-April 3 2019 Atlanta GA Background Xuanwei a rural county is located in the northeast of Yunnan Province China According to a national retrospective survey on cancer mortality during 1973-1975 the highest mortality rate of lung cancer in Xuanwei was 5 3 times higher than that in rural areas nationwide Age standardized mortality rates

Comprehensive genomic profiling of small cell lung cancer

Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential Small cell lung cancer (SCLC) is one of the deadliest malignancies and accounts for nearly 15% of lung cancers Previous study had revealed the genomic characterization of SCLC in Western patients However little is known about that in Chinese SCLC patients Methods

Squamous

Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC) It is the second most prevalent type of lung cancer after lung adenocarcinoma and it originates in the bronchi Its tumor cells are characterized by a squamous appearance similar to the one observed in epidermal cells Squamous-cell carcinoma of the lung is strongly associated with tobacco

Beyond adenocarcinoma: current treatments and future

Lung cancer encompasses a diverse spectrum of histologic subtypes Until recently the majority of therapeutic advances were limited to the minority of patients with adenocarcinoma With the advent of comprehensive genomic profiling of squamous and small cell lung

Comprehensive genomic profiles of small cell lung cancer

This work was supported by the German Cancer Aid (Deutsche Krebshilfe) as part of the small cell lung cancer genome sequencing consortium (grant ID: 109679 to R K T M P R B P N M V and S A H ) Further support was provided by the Korea Research Foundation (KRF 2011-0030105 grant to S J J ) Additional funding was provided by the NIH (5R01CA114102-08 to J S ) the German Ministry of

Immune Checkpoint Inhibitor (ICPI) Efficacy and Resistance

Analysis of the TCGA lung aCa dataset revealed MET SV (2 8%) linked with immune activation gene expression profiles (p Conclusions Although TMB powerfully predicts ICPI outcome independent of tumor cell PD-L1 expression considering GA in STK11 BRAF or MET may significantly increase the precision and improve outcomes when using genomics with IHC to guide to ICPI selection

Immunotherapy in small

Management of small cell lung cancer (SCLC) has not changed over the last decades In more recent years alterations of DNA repair machinery and other molecular pathways have been identified in SCLC and preclinical data suggest that dysregulation of these pathways might offer new therapeutic opportunities While immune checkpoint inhibitors (ICIs) have had a major impact on the clinical

dual chEcKpoint abrogation is synErgistic in KRAS

Comprehensive genomic profiles of small cell lung cancer Nature 2015 524:47–53 Major finding: Coinhibition of CHK1 and MK2 synergistically stimulates apoptosis in KRAS-mutant cancer cells concept: KRAS- and BRAF-mutant tu-mors exhibit genotoxic stress that in-duces tonic activation of CHK1 and MK2 impact: Combined inhibition of CHK1

Title: Comprehensive Genomic Profiles of Small Cell Lung

Title: Comprehensive Genomic Profiles of Small Cell Lung Cancer and Other Pulmonary Neuroendocrine Tumors Julie George PhD Research associate at the Department of Translational Genomics Medical Faculty University of Cologne Cologne Germany Speaker Hiroyuki Mano MD PhD Professor Department of Cellular Signaling Graduate School of Medicine The University of Tokyo

Clinical characteristics and prognostic value of the KRAS

The KRAS mutation is the second most common genetic variant in Chinese non-small cell lung cancer (NSCLC) patients At the 2019th World Conference of Lung Cancer the KRAS G12C-specific inhibitor AMG510 showed promising results in the phase I clinical trial However the frequency clinical characteristics and prognostic significance of the KRAS G12C mutation in Chinese NSCLC patients

Online customer service

Welcome ! If you have any questions or suggestions about our products and services,please feel free to tell us anytime!